Stress, Hormones, and Eating

• Status: Completed
• Trial end date: 2011-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

The investigators will develop a measure of endogenous opioid tone that might serve as a biological marker for drive for palatable food. Using a 'naltrexone probe,' the investigators will assess whether individual response to one dose of an opioid receptor antagonist, naltrexone, is related to non-homeostatic eating in non-pregnant women.

Hypothesis 1: Naltrexone Response will be related to non-homeostatic eating.

Hypothesis 2: Response profiles to the 25 mg dose will be slightly less in magnitude than the 50 mg dose. However, responses will be similarly related to non-homeostatic eating measures.

Hypothesis 3: Response to naltrexone will be highly stable within individuals across time, in the absence of an intervention.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of California, San Francisco
• Treatments: Naltrexone

Criteria

Inclusion Criteria:

• Women

• Age > 20 to 45 years (pre-menopausal women)

• BMI > 30 and no larger than BMI = 40 or 300 pounds

Exclusion Criteria:

• Inability to provide informed consent or speak English

• Needle phobic or fainting in response to blood draw

• Diabetes

• Currently pregnant or breastfeeding

• Currently Smoke

• Bulimia (Binge Eating Disorder is common among the obese, and allowed)

• Pacemaker

• Shift Worker

• Beta Blocker Medication use

• Liver Medication use

• Weight Loss Medication use

• Chronic current use of cortisol containing medications

• Kidney Disease (based on elevated Blood Urea Nitrogen and Creatinine)

• Illegal Drug Use (presence in urine)

• Liver Cirrhosis or Acute hepatitis (based on elevated Alanine transaminase)

• Substance abuse, mental health, or medical condition that, in the opinion of investigators, will affect study outcomes (e.g., hypertension, severe food allergies).